Interestingly, we found with the RUV-III normalized data that higher expression of the FOXA1 gene is associated with poorer outcome in the luminal B subtype, a conclusion that was obscured by the variation in tumor purity of the TCGA RNA-seq data (Extended Data Fig. 1f). This evidence concerns the gene FOXA1 and neoplasm.